MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology

MyBiotics Pharma, a microbiome therapeutics company, announced today that it has received an investment from Mii Fund, a partnership with Maruho Co. Ltd., Japan's preeminent leader in dermatology. About Dermatology and the Microbiome About MyBiotics MyBiotics discovers and develops microbiome-based products aimed at restoring microbiome equilibrium for the therapeutics and food markets. MyBiotics' technologies are effective for single microbes, complex microbial consortia and whole microbiome products, and are integrated with a computational AI platform which enables the design of unique microbial consortia and whole microbiome profiles. The Company's pipeline includes MBX-SD-201 and MBX-SD-202, for Clostridium difficile Infection (CDI) developed for oral delivery, that may become the first alternative for fecal microbiota transplant (FMT). MBX-SD-202 is planned to enter Phase I clinical studies in 2021. Additional products in the pipeline focus on woman's health, gastro and oncology indications, as well as probiotics and prebiotic programs. For additional information, please visit www.mybiotics-pharma.com or connect with us on LinkedIn.
（以上内容由医药魔方AI生成）